

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-19 (Cancelled).

20. (New) A pharmaceutical composition, which composition comprises:  
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,  
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,  
metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and  
a pharmaceutically acceptable carrier therefor,  
wherein the carrier is arranged to provide a modified release of at least one of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

21. (New) A composition according to claim 20, wherein the carrier is arranged to provide a modified release of both of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

22. (New) A composition according to claim 20, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof is

5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, or a pharmaceutically acceptable solvate thereof and wherein said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof is metformin hydrochloride, or a pharmaceutically acceptable solvate thereof.

23. (New) A composition according to claim 21, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, or a pharmaceutically acceptable solvate thereof and wherein said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof is metformin hydrochloride, or a pharmaceutically acceptable solvate thereof.

24 (New) A composition according to any one of claims 20-23, wherein the modified release is a delayed release.

25. (New) A composition according to claim 24, wherein the composition is in the form of an enteric tablet formulation.

26. (New) A composition according to claim 25, wherein the enteric coated tablet is a single layer tablet.

27. (New) A composition according to claim 25, wherein the enteric coated tablet is a multi-layer tablet.

28 (New) A composition according to claim 25, wherein the tablet is coated with a gastric resistant polymer.

29. (New) A composition according to claim 28, wherein the gastric resistant polymer is selected from the group consisting of Eudragit L100-55, methacrylates, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate.

30. (New) A composition according to claim 28 wherein the gastric resistant polymer is selected from the group consisting of Aquateric, Sureteric and HPMCP-HP-555.

31. (New) A composition according to any one of claims 20-23, wherein the modified release is a sustained release.

32. (New) A composition according to claim 31, wherein the sustained release is provided by a sustained release matrix selected from the group of matrices consisting of: disintegrating, non- disintegrating and eroding matrices.

33. (New) A composition according to claim 32, wherein the non-disintegrating matrix is provided by incorporating one or more members of the group consisting of: Eudragit RS, methacrylates, cellulose acetates, hydroxypropyl methylcellulose phthalate, Carbopol 971P or HPMCP-HP-55S into said matrix.

34. (New) A composition according to claim 32, wherein the disintegrating matrix is provided by incorporating one or more members of the group consisting of: methacrylates, methylcellulose and Methocel K4M into said matrix.